C.Q.Massó’s nutraceuticals reinforce its presence in the Asian market
October 11, 2019
C.Q.Massó’s and Green Plants Extract to strengthen its presence in the Asian market
October 8, 2022
The prestigious journal Nutrients MDPI has published the first study of Saffr’Activ on ADHD disease: “Effectivity of Saffron Extract (Saffr’Activ) on Treatment for Children and Adolescents with Attention Deficit/Hyperactivity Disorder (ADHD): A Clinical Effectivity Study Amazing evidences, in comparison with drug methylphenidate.” This study compares the efficacy of saffron and the usual treatment with methylphenidate, using objective and pen-and-paper tests. We performed a non-randomized clinical trial with two groups, methylphenidate (n = 27) and saffron (n = 36), in children and adolescents aged 7 to 17. Results show that the efficacy of saffron is comparable to that of methylphenidate. Saffron is more effective for treating hyperactivity symptoms, while methylphenidate is more effective for inattention symptoms.
Find the whole article here: Open Access
For further information regarding Saffr’Activ, our saffron extract: saffr’activ.com
